4D Molecular Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
4D Molecular Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-94.8%
Buyback Yield
Total Shareholder Yield | -94.8% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth
Nov 244D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 104D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if FDMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FDMT's dividend payments have been increasing.
Dividend Yield vs Market
4D Molecular Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (FDMT) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.2% |
Industry Average (Biotechs) | 2.3% |
Analyst forecast (FDMT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate FDMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FDMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FDMT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FDMT has not reported any payouts.